Valneva SE (EPA:VLA)
4.178
-0.168 (-3.87%)
Oct 20, 2025, 1:43 PM CET
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
€280,467
Profits / Employee
€95,773
Market Cap
746.34M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 713 | 37 | 5.47% |
Dec 31, 2023 | 676 | -43 | -5.98% |
Dec 31, 2022 | 719 | -43 | -5.64% |
Dec 31, 2021 | 762 | 262 | 52.40% |
Dec 31, 2020 | 500 | -21 | -4.03% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 153,498 |
emeis Société anonyme | 83,494 |
Sanofi | 82,878 |
Eurofins Scientific SE | 62,696 |
Clariane SE | 61,798 |
bioMérieux | 14,754 |
Sartorius Stedim Biotech | 9,901 |
Virbac | 6,365 |
Valneva SE News
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 6 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 11 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 13 days ago - Valneva SE (VALN) Lowers 2025 Sales Forecast Amid Vaccine Setback - GuruFocus
- 13 days ago - Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing - Seeking Alpha
- 13 days ago - Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates - GlobeNewsWire
- 16 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 20 days ago - Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ - Nasdaq